Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:5:103-9.
doi: 10.2147/MDER.S37831. Epub 2012 Dec 14.

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study

Daphne T Adelman  1 , Andrea Burgess, Philippa R Davies
Affiliations

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study

Daphne T Adelman et al. Med Devices (Auckl). 2012.

Abstract

The somatostatin analogs (SSAs) lanreotide Autogel/Depot and octreotide long-acting release are used to treat acromegaly and neuroendocrine tumors. The present study evaluated opinions on SSA injection devices, including a recently approved lanreotide new device (lanreotide-ND), among nurses in Europe and the USA. Nurses injecting SSAs for at least three patients per year (n = 77) were interviewed regarding SSA devices. Device attributes were rated via questionnaire; nurses were then timed administering test injections with lanreotide-ND and octreotide long-acting release. The most important delivery system attributes were easy/convenient preparation and injection (ranked in the top five by 70% of nurses), low clogging risk (58%), and high product efficacy (55%). Compared with the octreotide long-acting release device, lanreotide-ND scored higher on 15/16 attributes, had shorter mean preparation and administration time (329 versus 66 seconds, respectively; P ≤ 0.01) and a higher overall preference score (70 versus 114, respectively; P ≤ 0.01). The five most important lanreotide-ND attributes were: prefilled device, confidence a full dose was delivered, low clogging risk, easy/convenient preparation and injection, and fast administration. These device features could lead to improvements in clinical practice and benefit patients/caregivers who administer SSAs at home.

Keywords: device; lanreotide; nurse; octreotide; somatostatin analog.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Device try-out: time taken to prepare and administer test injections with octreotide LAR and lanreotide-ND. Note:aOne nurse was unable to finalize the injection due to a clogging incident and was excluded. Abbreviations: LAR, long-acting release; ND, new device.
Figure 2
Figure 2
Evaluation of octreotide LAR and lanreotide-ND: mean evaluation scores for each device attribute (scale of one to ten). Notes: Device attributes are labeled clockwise in order of importance to nurses (ie, confidence that a full dose has been delivered = most important and self-injection possible = least important) based on the mean evaluation score obtained in the first part of the interview. aAttributes weighted by importance to nurses; bdifference: P < 0.01. Abbreviations: LAR, long-acting release; ND, new device.
See this image and copyright information in PMC

References

    1. Melmed S. Medical progress acromegaly. N Engl J Med. 2006;355(24):2558–2573. - PubMed
    1. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol. 2008;286(1–2):238–250. - PubMed
    1. Somatuline® Depot (lanreotide) injection [prescribing information] Paris: Ipsen Pharma; 2011.
    1. Biermasz NR, van den Oever NC, Frolich M, et al. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf) 2003;58(3):228–295. - PubMed
    1. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2004;61(2):224–231. - PubMed